TARGET FOR NSCLC: The Advancing Research into Genomic Pathways and use of EGFR Therapies
The goal of this initiative is to increase clinicians’ knowledge and improve their competence in understanding the latest advances in targeting genomic pathways for the treatment of non-small cell lung cancer (NSCLC) through a review of the current and ongoing research/clinical trials focused on new and emerging EGFR-based therapies.
This program is designed to meet the educational needs of oncologists, physician assistants, nurse practitioners, nurses, and other health care professionals involved in the treatment and management of patients with NSCLC.
Following this activity, participants should be able to:
- Review the importance of testing for genetic mutations to assist in treatment decision-making
- Discuss updated recommendations for use of drugs targeting EGFR+ mutations and evaluate potential applications of emerging therapies targeting EGFR+ mutations
- Describe mechanisms of resistance in treatment of EGFR+ NSCLC and develop strategies to overcome resistance to EGFR+ therapies
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have no relevant financial relationships with ineligible companies to disclose.
Renato Martins, MD
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Jose Pacheco, MD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Blueprint Medicines: Scientific Advisor
Checkmate Pharmaceuticals: Grant/Research Support
Daiichi-Sankyo Co.: Grant/Research Support
Gerson Lehrman Group, Inc.: Scientific Advisor
Janssen Phamaceutica Products, LP: Product/Speakers Bureau
Jiangsu Hengrui Pharmaceuticals: Scientific Advisor
Jazz Pharmaceuticals Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Scientific Advisor
Pfizer Inc.: Grant/Research Support; Scientific Advisor
Research America: Scientific Advisor
Takeda Pharmaceuticals North America, Inc.: Scientific Advisor
Debora Bruno, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Tempus Labs, Inc.: Consulting Fee
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until October 12, 2022. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing